SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD - News), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, is scheduled to provide a corporate overview, including a discussion about the clinical development program for the Company’s lead product candidate, picoplatin, at two upcoming investor conferences:
